Qualigen Therapeutics Reports Increased Losses and Cash Crunch Amid Financial Challenges

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has released its quarterly report for the period ended March 31, 2025, revealing a mix of challenges and potential opportunities within the organization.

Here are key points extracted from the income statement and financial condition:

• Total Expenses: Increased to $2.7 million from $1.4 million in the prior year, driven largely by a 135% spike in general and administrative expenses, particularly in investor relations.
• Loss from Operations: The company reported a loss from operations of $(2.7 million), compared to a $(1.4 million) loss in the same period last year.
• Net Loss: The total net loss stood at $(2.65 million), marking a rise from $(2.03 million) year-over-year.
• Cash and Cash Equivalents: At March 31, 2025, the company had only $30,210 in cash, down significantly from $1.17 million at the start of the quarter.
• Accumulated Deficit: The accumulated deficit has reached $125.7 million, highlighting ongoing financial struggles.
• Credit Loss Expense: Notably expanded to $197,000 as the company accounts for potential losses associated with short-term notes receivable to Marizyme.
• Interest Income: Increased to $112,953, a reflection of accrued interest from the Marizyme Notes.
• Investor Relations Costs: Represented approximately 51% of operating expenses for the quarter, indicating a strong focus on raising additional funds.

Challenges:

• The substantial existence of an accumulated deficit raises concerns regarding the company's financial health and ability to secure necessary funding.
• The company is in a liquidity crisis with just $30,210 in cash, necessitating urgent funding to support operations.
• Ongoing increases in general and administrative expenses could indicate inefficiencies in the management structure.
• The quarterly financials signal a potential delisting from NASDAQ if fiscal improvement is not demonstrated.

Opportunities:

• The ongoing Co-Development Agreement with Marizyme may yield quarterly royalty payments, enabling a new revenue stream contingent on successful commercialization.
• Management's strategic review of operations could lead to effective adjustments aimed at improving financial and operational outcomes.
• Potential future funding rounds-including a planned private placement-could offer necessary liquidity to support operational goals.

In summary, Qualigen Therapeutics remains in a precarious financial position but with critical developments underway that could influence its operational landscape. The management must prioritize financial stability while navigating the challenges of increased expenses and an acute cash flow situation.